Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sabrina Kuttruff-Coqui"'
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46977681ac8a5cbd10f04dd9e8a6e33
https://doi.org/10.1158/2326-6066.cir-22-0444
https://doi.org/10.1158/2326-6066.cir-22-0444
Autor:
Dominik Maurer, Borje S. Andersson, Jens Fritsche, Arun Satelli, Sabrina Kuttruff-Coqui, Kerstin Guenther, Carsten Reinhardt, Steffen Walter, Mamta Kalra, Ali Mohamed, Apostolia Maria Tsimberidou, Rita Ort, Kerry Sieger, Norbert Hilf, Amir Alpert, Anna Nowak, Becky Norris, Toni Weinschenk, David Vining, Oliver Schoor, Fabian Richter, Patrick Hwu, Zoe Coughlin, Cassian Yee, Regina Mendrzyk, Harpreet Singh, Claudia Wagner
Publikováno v:
Regular and young investigator award abstracts.
Background ACTolog (IMA101) is a personalized multi-target adoptive cell therapy (ACT) approach in which autologous T-cell products are redirected against multiple novel defined peptide-HLA (pHLA) cancer targets identified by the target discovery pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71a6921cc055df88f8c205a850f3d59f
https://doi.org/10.1136/jitc-2020-sitc2020.0293
https://doi.org/10.1136/jitc-2020-sitc2020.0293
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Oliver Schoor, Jens Fritsche, Joseph F. Costello, Toni Weinschenk, Norbert Hilf, Gary Kohanbash, Josie Hayes, Payal Watchmaker, Sabrina Kuttruff-Coqui, Hideho Okada, Samuel J. Shelton, Colette Song, Diego Carrera, Michael C. Oldham, Soeren Mueller, Harpreet Singh
Publikováno v:
Neuro-Oncology. 19:vi124-vi124
Diffuse infiltrating low-grade gliomas (WHO grade II or III) are slow-growing primary brain tumors, but are considered malignant due to their invasive growth with a high risk of recurrence and progression to higher-grade tumors. While novel immunothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dc182c56fbc4bd4bcb6a8fad8c391fb
https://doi.org/10.1093/neuonc/nox168.510
https://doi.org/10.1093/neuonc/nox168.510
Autor:
Ghazaleh Tabatabai, Peter Lewandrowski, Monika Stieglbauer, Stefan Stevanovic, Sandra Heesch, Per thor Straten, Jordi Rodon, Ugur Sahin, Juan Sahuquillo, Colette Song, Valérie Dutoit, Randi Kristina Feist, Christian H. Ottensmeier, Francisco Martínez-Ricarte, Sabrina Kuttruff-Coqui, Hideho Okada, Bernhard Rössler, Judith R. Kroep, Wick Wolfgang, Jens Fritsche, Regina Mendryzk, Norbert Hilf, Karoline Laske, Hans-Georg Rammensee, Carsten Reinhardt, Marij Schoenmaekers-Welters, Harpreet Singh-Jasuja, Stevermann Lea, Toni Weinschenk, Michael Platten, Sjoerd H. van der Burg, Marco Skardelly, Katrin Frenzel, Ulrik Lassen, Christoph Huber, Valesca Bukur, Arie Admon, Berta Ponsati, David Capper, Hans Skovgaard Poulsen, Pierre-Yves Dietrich, Miriam Meyer, Anna Paruzynski, Nina Pawlowski, Sebastian Kreiter, Cécile Gouttefangeas, Andreas von Deimling, Martin Löwer, Jordi Piro
Publikováno v:
Cancer Research. 76:2654-2654
The Glioma Actively Personalized Vaccine Consortium (GAPVAC; funded by the European Union Framework 7 Program) aims at treating newly diagnosed glioblastoma (GB) patients with two distinct actively personalized vaccines (APVACs). Resected tumor mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89c12cda11f18b33762df595819c6a64
https://doi.org/10.1158/1538-7445.am2016-2654
https://doi.org/10.1158/1538-7445.am2016-2654